JP2002508387A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508387A5
JP2002508387A5 JP2000539042A JP2000539042A JP2002508387A5 JP 2002508387 A5 JP2002508387 A5 JP 2002508387A5 JP 2000539042 A JP2000539042 A JP 2000539042A JP 2000539042 A JP2000539042 A JP 2000539042A JP 2002508387 A5 JP2002508387 A5 JP 2002508387A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000539042A
Other languages
Japanese (ja)
Other versions
JP4413428B2 (ja
JP2002508387A (ja
Filing date
Publication date
Priority claimed from US08/991,743 external-priority patent/US6229002B1/en
Application filed filed Critical
Publication of JP2002508387A publication Critical patent/JP2002508387A/ja
Publication of JP2002508387A5 publication Critical patent/JP2002508387A5/ja
Application granted granted Critical
Publication of JP4413428B2 publication Critical patent/JP4413428B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000539042A 1997-12-16 1998-04-29 血小板由来増殖因子（ｐｄｇｆ）核酸リガンド複合体 Expired - Fee Related JP4413428B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/991,743 1997-12-16
US08/991,743 US6229002B1 (en) 1995-06-07 1997-12-16 Platelet derived growth factor (PDGF) nucleic acid ligand complexes
PCT/US1998/009050 WO1999031119A1 (en) 1997-12-16 1998-04-29 Platelet derived growth factor (pdgf) nucleic acid ligand complexes

Publications (3)

Publication Number Publication Date
JP2002508387A JP2002508387A (ja) 2002-03-19
JP2002508387A5 true JP2002508387A5 (enExample) 2005-12-22
JP4413428B2 JP4413428B2 (ja) 2010-02-10

Family

ID=25537513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539042A Expired - Fee Related JP4413428B2 (ja) 1997-12-16 1998-04-29 血小板由来増殖因子（ｐｄｇｆ）核酸リガンド複合体

Country Status (11)

Country Link
US (5) US6229002B1 (enExample)
EP (1) EP1042348B1 (enExample)
JP (1) JP4413428B2 (enExample)
AU (1) AU749273B2 (enExample)
CA (1) CA2315271C (enExample)
CY (1) CY1114352T1 (enExample)
DK (1) DK1042348T3 (enExample)
ES (1) ES2426160T3 (enExample)
PT (1) PT1042348E (enExample)
SI (1) SI1042348T1 (enExample)
WO (1) WO1999031119A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6376604B2 (en) 1999-12-22 2002-04-23 Shearwater Corporation Method for the preparation of 1-benzotriazolylcarbonate esters of poly(ethylene glycol)
WO2001087351A1 (en) * 2000-05-17 2001-11-22 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to pdgf
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
WO2002067849A2 (en) * 2001-02-26 2002-09-06 Sabina Glozman Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents
PT1401853E (pt) 2001-05-25 2010-12-07 Univ Duke Modulador de oligonucleotídeos
EP1481090A4 (en) * 2002-02-15 2006-08-09 Somalogic Inc METHOD AND REAGENTS FOR DETECTING BINDING OF TARGET MOLECULES BY NUCLEIC ACID ELECTRODES
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
CA2487809A1 (en) * 2002-06-18 2003-12-24 Archemix Corp. Aptamer-toxin molecules and methods for using same
JP2005533862A (ja) * 2002-07-25 2005-11-10 アーケミックス コーポレイション 調節されたアプタマー治療剤
AU2003294437A1 (en) * 2002-11-21 2004-06-18 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US20090053138A1 (en) * 2002-11-21 2009-02-26 Preiss Jeffrey R Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics
WO2006050498A2 (en) 2004-11-02 2006-05-11 Archemix Corp. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en) * 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP1620547B1 (en) 2003-04-21 2014-06-18 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20040260034A1 (en) 2003-06-19 2004-12-23 Haile William Alston Water-dispersible fibers and fibrous articles
US7892993B2 (en) 2003-06-19 2011-02-22 Eastman Chemical Company Water-dispersible and multicomponent fibers from sulfopolyesters
US8513147B2 (en) 2003-06-19 2013-08-20 Eastman Chemical Company Nonwovens produced from multicomponent fibers
AU2004268614C1 (en) * 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
HUE050481T2 (hu) * 2004-02-12 2020-12-28 Archemix Llc Aptamer terapeutikumok, amelyek használhatók komplementtel kapcsolatos rendellenességek kezelésében
EP1756138A4 (en) * 2004-03-05 2009-07-01 Archemix Corp APTAMERS FACILITATED TO THE FAMILY OF HUMAN IL-12 CYTOKINS AND THEIR USE AS THERAPEUTICS AGAINST AUTOIMMUNE DISEASES
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
US7579450B2 (en) * 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
DE602005012155D1 (de) * 2004-11-03 2009-02-12 Liplasome Pharma As Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid-derivaten und ihre therapeutische verwendung
DE502005009920D1 (de) * 2004-11-29 2010-08-26 Noxxon Pharma Ag Vasopressin bindende l-nukleinsäure
US20090075342A1 (en) * 2005-04-26 2009-03-19 Sharon Cload Metabolic profile directed aptamer medicinal chemistry
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
EP1907590B1 (en) 2005-06-30 2012-09-19 Archemix LLC T7 rna polymerase and methods for the generation of fully 2'-modified nucleic acid transcripts
US7922000B2 (en) * 2006-02-15 2011-04-12 Miraial Co., Ltd. Thin plate container with a stack of removable loading trays
CA3009846C (en) 2006-03-08 2021-08-31 David Epstein Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
US8207298B2 (en) * 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8512519B2 (en) 2009-04-24 2013-08-20 Eastman Chemical Company Sulfopolyesters for paper strength and process
EP3028707A1 (en) * 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
US8318923B2 (en) * 2009-06-03 2012-11-27 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
WO2012054668A2 (en) * 2010-10-21 2012-04-26 Useastman Chemical Company Sulfopolyester binders
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
US8735367B2 (en) * 2011-06-27 2014-05-27 University Of Utah Research Foundation Small molecule-dependent split aptamer ligation
ES2742284T3 (es) 2012-03-28 2020-02-13 Somalogic Inc Aptámeros contra PDGF y VEGF y su utilización en el tratamiento de afecciones mediadas por PDGF y VEGF
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103290019B (zh) * 2013-06-14 2014-03-12 严鹏科 一种动脉粥样硬化的靶向适配子及其制备方法和应用
EA201690212A8 (ru) * 2013-07-12 2016-08-31 Офтотек Корпорейшн Способы лечения или профилактики офтальмологических патологических состояний
CA3221709A1 (en) 2013-09-09 2015-03-12 Somalogic Operating Co., Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
BR112016021547A2 (pt) 2014-03-17 2017-10-03 Glaxosmithkline Ip Dev Ltd Aptâmeros para envio tópico
WO2019109046A1 (en) 2017-11-30 2019-06-06 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB462145A (en) 1934-11-19 1937-03-03 Albert Von Lom Improvements in or relating to drying plants
DE3588239T3 (de) 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
DE69008521T2 (de) 1989-03-07 1994-10-20 Genentech Inc Kovalente konjugate von lipiden und oligonukleotiden.
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
WO1995006659A1 (en) 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
EP0537299A1 (en) 1990-03-29 1993-04-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
EP0572529A4 (en) 1991-02-21 1994-11-02 Gilead Sciences Inc SPECIFIC APTAMER OF BIOMOLECULES AND PROCESS FOR PRODUCING THE SAME.
US5171217A (en) 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
CA2082411A1 (en) 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
US6172208B1 (en) 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
IL108206A0 (en) 1993-01-06 1994-04-12 Univ Johns Hopkins Oligomers having improved stability at acid ph
EP0689465A1 (en) 1993-03-18 1996-01-03 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
AU7019794A (en) 1993-05-26 1994-12-20 Genta Incorporated Oligomer conjugates and their use
AU7102594A (en) 1993-06-09 1995-01-03 Pharmagenics, Inc. Oligonucleotides which inhibit hiv protease function
AU7175094A (en) 1993-06-18 1995-01-17 Pharmagenics, Inc. Inhibition of interferon-gamma with oligonucleotides
CA2169536A1 (en) 1993-09-08 1995-03-16 Gilead Sciences, Inc. Nucleic acid ligands and improved methods for producing the same
EP1889910A3 (en) 1993-09-17 2009-09-02 SomaLogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0824541B1 (en) 1995-05-04 2009-12-16 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6207816B1 (en) 1995-06-02 2001-03-27 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to growth factors
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands

Similar Documents

Publication Publication Date Title
BE2014C048I2 (enExample)
JP2001519638A5 (enExample)
JP2002508387A5 (enExample)
IN192936B (enExample)
JP2001514030A5 (enExample)
MX214854B (enExample)
JP2002500376A5 (enExample)
JP2001525207A5 (enExample)
JP3076551B6 (enExample)
BRPI9917863A2 (enExample)
JP2541338C (enExample)
JP2619909C (enExample)
IN190582B (enExample)
IN188412B (enExample)
JP2509608Z (enExample)
JP2527297Z (enExample)
JP2592956C (enExample)
JP2582019C (enExample)
CN3078569S (enExample)
CN3078087S (enExample)
CN3079837S (enExample)
CN3076419S (enExample)
CN3075068S (enExample)
CN3076421S (enExample)
CN3077688S (enExample)